ATE356206T1 - Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen - Google Patents

Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Info

Publication number
ATE356206T1
ATE356206T1 AT98949385T AT98949385T ATE356206T1 AT E356206 T1 ATE356206 T1 AT E356206T1 AT 98949385 T AT98949385 T AT 98949385T AT 98949385 T AT98949385 T AT 98949385T AT E356206 T1 ATE356206 T1 AT E356206T1
Authority
AT
Austria
Prior art keywords
eso
cancer antigen
cag
gene coding
human cancer
Prior art date
Application number
AT98949385T
Other languages
English (en)
Inventor
Rong Fu Wang
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE356206T1 publication Critical patent/ATE356206T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
AT98949385T 1997-10-08 1998-09-21 Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen ATE356206T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6142897P 1997-10-08 1997-10-08

Publications (1)

Publication Number Publication Date
ATE356206T1 true ATE356206T1 (de) 2007-03-15

Family

ID=22035712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949385T ATE356206T1 (de) 1997-10-08 1998-09-21 Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Country Status (6)

Country Link
EP (1) EP1021535B1 (de)
AT (1) ATE356206T1 (de)
AU (1) AU9572098A (de)
DE (1) DE69837273T2 (de)
ES (1) ES2281935T3 (de)
WO (1) WO1999018206A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
US6673350B2 (en) * 1997-05-05 2004-01-06 Ludwig Institute For Cancer Research Tumor associated peptide and uses thereof
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
EP1001022A1 (de) * 1998-10-16 2000-05-17 Boehringer Ingelheim International GmbH CAMEL, ein alternatives Translationsprodukt des Tumorantigenes LAGE-1
MXPA01011250A (es) * 1999-05-06 2002-08-12 Univ Wake Forest Composiciones y metodos para identificar antigenos que producen una respuesta inmune.
FR2795415B1 (fr) * 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
DE19936563A1 (de) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
US6689742B1 (en) * 2000-02-25 2004-02-10 Chancellors, Masters And Scholars Of The University Of Oxford NY-ESO-1 peptide derivatives, and uses thereof
AU776058B2 (en) * 1999-11-15 2004-08-26 Chancellor, Masters And Scholars Of The University Of Oxford, The NY-ESO-1 nonapeptide derivatives, and uses thereof
EP2311950A1 (de) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Neuartige MHC Klasse II restringierte T-Zellepitope des Krebsantigens NY ESO-1
US6506875B1 (en) * 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
FR2830940B1 (fr) * 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
PL1786908T3 (pl) * 2004-08-18 2010-08-31 Bayer Cropscience Ag Rośliny o zwiększonej aktywności plastydowej enzymu R3 fosforylującego skrobię
EP2155241A4 (de) * 2007-05-04 2010-06-02 Boris Skurkovich Verhinderung von krebs durch immunisierung
CA2717499A1 (en) 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
EP3013789B1 (de) * 2013-06-28 2020-03-04 Auckland Uniservices Limited Aminosäure- und peptidkonjugate und konjugationsverfahren
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
EP3419962A4 (de) 2016-02-26 2020-03-11 Auckland Uniservices Limited Aminosäure- und peptidkonjugate und konjugationsverfahren
JP2019514939A (ja) * 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 標的組織における自然免疫応答の治療的誘発

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
EP0970206B1 (de) * 1997-01-27 2008-07-23 Ludwig Institute For Cancer Research Lage-1 tumor-assozierte nukleinsäuren

Also Published As

Publication number Publication date
WO1999018206A3 (en) 1999-08-05
DE69837273D1 (de) 2007-04-19
ES2281935T3 (es) 2007-10-01
AU9572098A (en) 1999-04-27
DE69837273T2 (de) 2008-01-31
WO1999018206A2 (en) 1999-04-15
EP1021535B1 (de) 2007-03-07
EP1021535A2 (de) 2000-07-26

Similar Documents

Publication Publication Date Title
ATE356206T1 (de) Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
WO2001055393A3 (en) Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
PT882130E (pt) Antigenio de cancro humano de proteina 1 relacionada com a tirosinase e gene que o codifica
TR200200633T2 (tr) Yeni streptococcus antijenleri
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
DK1645631T3 (da) Neisseria antigener og præparater
NO980883D0 (no) Forbindelser og fremgangsmåter for immunterapi og diagnose av tuberkulose
DE60136054D1 (de) Apoptose-induzierendes polypeptid
DE69634918D1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
DE69928925D1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2003068813A3 (en) Group b streptococcus antigen
WO2003106478A3 (en) ANTIBODIES BINDING TO ALPHAE INTEGRIN
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
ATE451461T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
PT1112366E (pt) Polinucleotideos e polipeptideos basb033 da neisseria meningitidis e suas utilizacoes
TR200100741T2 (tr) Moraxella catarrhalis BASB034 polipeptidleri ve kullanımları
EP1806403A3 (de) Neues humanes Krebsantigen NY ESO 1/CAG-3 und dafür kodierendes Gen
DK1082435T3 (da) Proteiner og gener fra Moraxella catarrhalis, antigener, antistoffer og anvendelser
EP1191096A4 (de) Neues protein und dessen dns
ATE525470T1 (de) Antigene epitope des faktors viii, inhibitoren dagegen, und deren verwendungen
DE69617255D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties